Strategic Initiative Update: CDMO Mandate Execution

Morepen Laboratories Limited has commenced commercial supplies under its recently announced ₹825 crore Contract Development and Manufacturing Organization (CDMO) mandate.

Commercial Dispatch Completion

The first commercial dispatch, valued at approximately ₹50 crore, was completed during Q1 FY2026-27 (April-June 2026). This marks the successful transition from the validation and qualification stage to the commercial execution stage of the CDMO program.

Scaling Plans and Future Supplies

The company expects to scale the program further in the coming quarter, with additional supplies of approximately ₹225 crore anticipated during Q2 FY2026-27 (July-September 2026). This scaling is subject to customer schedules and regulatory/commercial requirements.

Manufacturing Capacity Expansion

To support larger CDMO opportunities, Morepen is strengthening its manufacturing infrastructure:

  • Total reactor capacity is expected to reach approximately 600 KL by the end of Q2 FY2026-27
  • Further expansion plans target 800 KL and 1,000 KL capacity in subsequent phases

Management Commentary

Mr. Sanjay Suri, Managing Director, stated: "This is an important milestone in Morepen's transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities."

Strategic Significance

The commencement of commercial supplies reinforces Morepen's strategy to:

  • Build a scalable CDMO platform
  • Deepen customer partnerships
  • Participate in long-duration global manufacturing opportunities

Company Background

Morepen Laboratories Limited is a pharmaceutical and healthcare company with presence across APIs, finished formulations, diagnostics, and consumer healthcare. The company continues to strengthen its manufacturing, research, and regulatory capabilities to support growth across domestic and international markets.